Mesoblast Limited (ASX:MSB) Acquisition Of Angioblast Systems Inc. By Angioblast Stockholders

Melbourne, Oct 20, 2010 AEST (ABN Newswire) - Stockholders of United States adult stem cell company Angioblast Systems Inc. voted unanimously at a special stockholders' meeting held 19 October in favour of becoming a wholly-owned subsidiary of publicly listed global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY).

To increase its ownership of Angioblast from 32.8% to 100%, Mesoblast will issue approximately 94.6 million Mesoblast shares to Angioblast stakeholders. This acquisition will enable Mesoblast to broaden its product pipeline across a wide range of clinical indications including cardiovascular, oncology, eye, and diabetes, in addition to its orthopedic range of products.

The issuance of new shares is anticipated to occur shortly, subject to formal documentation and closure of the transaction.

Contact

Julie Meldrum Corporate Communications Director Mesoblast Limited Tel: +61-3-9639-6036 Mob: +61-419-228-128 Email: julie.meldrum@mesoblast.com www.mesoblast.com